RMH Holdings Valuation
Is 8570 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8570 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8570 (HK$0.36) is trading below our estimate of fair value (HK$126.62)
Significantly Below Fair Value: 8570 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8570?
Key metric: As 8570 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 8570's PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | S$6.85m |
| Market Cap | S$4.01m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -2.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8570's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
8357 Republic Healthcare | 1x | n/a | HK$54.9m |
2159 Mediwelcome Healthcare Management & Technology | 0.2x | n/a | HK$79.0m |
8307 Medicskin Holdings | 1.6x | n/a | HK$75.0m |
1406 Clarity Medical Group Holding | 1.2x | n/a | HK$216.9m |
8570 RMH Holdings | 0.6x | n/a | HK$23.3m |
Price-To-Sales vs Peers: 8570 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does 8570's PS Ratio compare vs other companies in the HK Healthcare Industry?
Price-To-Sales vs Industry: 8570 is good value based on its Price-To-Sales Ratio (0.6x) compared to the Hong Kong Healthcare industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is 8570's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8570's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
OrbusNeich Medical Group Holdings
HK$3.1b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$3.78
7D
-7.8%
1Y
-36.8%
Sinopharm Group
HK$63.3b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.30
7D
1.2%
1Y
5.8%
MicroPort Scientific
HK$11.1b
An investment holding company, engages in the manufacture, marketing, and sale of medical devices in the People’s Republic of China, North America, Europe, rest of Asia, South America, and internationally.
853
HK$6.01
7D
5.4%
1Y
-52.1%